Acute myeloid leukemia (AML) is a cancer that starts when a rapid growth of atypical bone marrow cells (myeloid cells) begins to interfere with the production of normal blood cells. Even after an apparently successful treatment with chemotherapy, patients with AML often relapse due to the survival of cells with a highly active energy metabolism. The aim of the current study was to assess whether the combination of conventional therapies and drugs targeting cell energy metabolism could help to circumvent the resistance of cancerous cells to treatment.
In order to better identify potential treatment resistant cells, the researchers first devised a scoring system rating energy metabolism in the cell mitochondria (the part of a cell which is responsible for energy production) of humans and mice. A higher ‘MitoScore’ was given to the hyperactive cells that demonstrated resistance to conventional chemotherapy.
By closely studying these cells after a combined treatment of cytarabine with newly FDA-approved BCL2-targeted therapy venetoclax, key mitochondrial mechanisms were found to result in the development of treatment resistance. By targeting these different mechanisms using specific mitochondrial inhibitors, the researchers were able to substantially delay relapse after therapy. Furthermore, such resistance could also be prevented by alternating cytarabine and azacytidine in association with venetoclax.
The study, recently published in the journal Nature Cancer, suggests that the results of this work could lead to promising new combinatory therapeutic strategies in AML. Indeed, not only does the work provide a scientific basis for alternating chemotherapy treatments in patients with higher ‘MitoScores’, but the range of effective mitochondrial inhibitors substantially broadens the landscape for targeted therapies.
Researchers Nathalie Nicot and Tony Kaoma, from the Translational Medicine Operations Hub of the LIH, were both intimately involved in the study, providing expertise in Translational Medicine and Computational Biomedicine respectively. Their combined work has helped to highlight “the pivotal role of mitochondrial metabolism in therapeutic resistance, with the hope that future patients could benefit from improved treatment outcomes.”
Tony KaomaBioinformatician, Integrated BioBank of Luxembourg
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.